During the corresponding time, Biolinerx Ltd saw a revenue deteriorated by -95.92 % year on year, While revenue at the Biolinerx Ltd 's corporate clients
Biolinerx Ltd's Comment on Sales, Marketing and Customers
The company utilizes contract manufacturers for the clinical and pre-clinical development of GLIX1 and motixafortide. Manufacturing responsibility for motixafortide is being transferred to Ayrmid. Under the Gloria License Agreement, the Gloria Licensee may also manufacture motixafortide in the future. The company retains rights to manufacture motixafortide for clinical development and commercialization in specific indications and territories. Due to long lead times and costs, manufacturing is expected to be conducted by single contract manufacturers. The company's laboratories in Modi’in, Israel support research and development but are not compliant with current good manufacturing practices (cGMP) and therefore cannot independently manufacture drug substances or products for clinical trials or commercial distribution. Third-party manufacturers must comply with cGMP and are subject to FDA and other regulatory inspections to ensure compliance. Non-compliance with regulations can result in legal and regulatory actions.
Biolinerx Ltd’s Comment on Sales, Marketing and Customers
The company utilizes contract manufacturers for the clinical and pre-clinical development of GLIX1 and motixafortide. Manufacturing responsibility for motixafortide is being transferred to Ayrmid. Under the Gloria License Agreement, the Gloria Licensee may also manufacture motixafortide in the future. The company retains rights to manufacture motixafortide for clinical development and commercialization in specific indications and territories. Due to long lead times and costs, manufacturing is expected to be conducted by single contract manufacturers. The company's laboratories in Modi’in, Israel support research and development but are not compliant with current good manufacturing practices (cGMP) and therefore cannot independently manufacture drug substances or products for clinical trials or commercial distribution. Third-party manufacturers must comply with cGMP and are subject to FDA and other regulatory inspections to ensure compliance. Non-compliance with regulations can result in legal and regulatory actions.
Sources:
Biolinerx Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Biolinerx Ltd’s corporate clients.
For your research, we’ve provided 9 tables on Biolinerx Ltd corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
100 %